Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Operations (Unaudited)

v3.21.2
Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended 9 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Operating expenses:        
Research and development $ 3,887,261 $ 2,455,822 $ 11,598,835 $ 5,166,485
Acquired in-process research and development 6,826,495 6,826,495
General and administrative 2,352,268 2,484,148 6,541,717 4,753,428
Loss from operations (6,239,529) (11,766,465) (18,140,552) (16,746,408)
Interest (income) expense (3,798) 10,344
Foreign exchange loss (1,513) (8,787) (16,837) (8,787)
Other income 125,501 125,501
Net loss $ (6,115,541) $ (11,779,050) $ (18,031,888) $ (16,744,851)
Share information:        
Net loss per share, basic and diluted $ (0.27) $ (1.05) $ (0.93) $ (2.23)
Weighted average shares outstanding, basic and diluted 22,502,202 11,263,559 19,482,287 7,518,091